CA-SCIENTIST.COM
23.3.2022 17:20:10 CET | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s supplier pre-assessment program, has been used to successfully complete an on-site assessment of the LIDE Biotech facility in Shanghai, China. VERIF.i was developed to help users on both sides of the Scientist.com marketplace improve quality standards and reduce indirect costs.
LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) Biotech is a translational medicine service provider that has delivered innovations in oncology translational research and immune-oncology for the past 11 years. LIDE was founded by overseas returnees Drs. Danyi Wen, Yizhun Zhu and others, with the goal of bringing together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. LIDE is committed to superior research quality; in 2015, it partnered with several large pharma and biotech companies to create a PDX Consortium Board with the goal of promoting and ensuring high PDX standards across China.
“At LIDE we hold ourselves to the highest industry standards by ensuring superior quality of our facilities and the world class scientists operating them,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “Together with other industry certifications, VERIF.i allows us to showcase our quality commitment across the industry in North America and Europe as well as in the growing Scientist.com marketplace.”
VERIF.i gives suppliers of regulated research services the opportunity to proactively communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection. Pre-assessments help suppliers such as LIDE Biotech demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.
“Even prior to the Covid-19 pandemic, on-site assessments of laboratories were difficult to complete owing to the high cost and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com . “VERIF.i addresses these challenges by creating a standardized process for both customers and suppliers. It also enables suppliers like LIDE to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About LIDE Biotech
LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. We do this through our unique access to fresh patient samples, received daily via our close hospital partnerships across China. These relationships combined with our proprietary kits, tumor sample kit, CRC kit, MiniPDX assay kit, and K-Cell kits, LIDE’s platform gives our clients the competitive edge to save time and budget. Based on this success, LIDE has built a robust database of over 1600+ PDX, CDX, and Cell Line models which grows daily. Our CRO services can be custom tailored based on what stage of the pre-clinical oncology drug development process you’re in, including clinical biopsy collection, in vitro/in vivo studies, transcription RNA and DNA analysis, and Immuno-Oncology capabilities.
LIDE Biotech will be at the American Association for Cancer Research Annual Meeting in New Orleans from April 10 – 13. Stop by First Floor Exhibit Hall D-H, Booth # 2057.
Watch LIDE Biotech’s Director of Immuno-Oncology, Dr. Bin Xie discuss current and novel Immuno-Oncology drug evaluation methods via humanized mouse models on a Scientist.com-hosted webinar.
Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.
About Scientist.com
Scientist.com’s mission is to empower and connect scientists worldwide. By transforming the way scientific research is performed, our Science as a Service® platform accelerates discoveries that prevent and cure disease, address climate change and help secure global food and energy supplies. We combine sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005725/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom